Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 | P23786 | 1/20 | 0.52 |
| ▸ | CPT1A | P50416 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 10/20 | 0.44 |
| ▸ | MLNR | O43193 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | VHL | P40337 | 3/20 | 0.41 |
| ▸ | ELOC | Q15369 | 2/20 | 0.41 |
| ▸ | ELOB | Q15370 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21696488 | 0.91 | CCR1 (0.53) | CPT2CPT1ACCR1ALDH1A1MAPT | |
| SCHEMBL16277207 | 0.89 | CCR1 (0.57) | CPT2CPT1ACCR1PKMVHL | |
| SCHEMBL25768321 | 0.86 | VHL (0.57) | CPT2CPT1ACCR1ALDH1A1MAPT | |
| SCHEMBL21697218 | 0.83 | VHL (0.56) | HRH3CYP3A4ALDH1A1PKMVHL | |
| SCHEMBL16277206 | 0.83 | FKBP1A (0.47) | ALDH1A1VHLELOCELOB | |
| SCHEMBL15126220 | 0.78 | VHL (0.53) | KMT2AALDH1A1VHL | |
| SCHEMBL15126160 | 0.78 | VHL (0.58) | CPT2CPT1ACYP3A4ALDH1A1PKM | |
| SCHEMBL15126384 | 0.77 | VHL (0.59) | CYP3A4ALDH1A1PKMVHLELOC | |
| SCHEMBL13570435 | 0.75 | VHL (0.52) | VHL | |
| SCHEMBL21696738 | 0.75 | VHL (0.52) | VHL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730862-B2 | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase | YALE UNIVERSITY (US) | 2020-08-04 | — | — | US | disclosed |
| EP-3608317-A1 | COMPOUNDS & METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS & OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | Yale University (US) | 2020-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730862-B2 | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase | VHL, MDM2, NEDD4 | CPT2 4145/4885CPT1A 4238/4885MEN1 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.